摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Dichloralphenazone | 480-30-8

中文名称
——
中文别名
——
英文名称
Dichloralphenazone
英文别名
1,5-dimethyl-2-phenylpyrazol-3-one;2,2,2-trichloroethane-1,1-diol
Dichloralphenazone化学式
CAS
480-30-8
化学式
C15H18Cl6N2O5
mdl
MFCD00867540
分子量
519.0
InChiKey
ATKXDQOHNICLQW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    68°
  • 溶解度:
    可溶于氯仿(少许)、DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    1.22
  • 重原子数:
    28
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    105
  • 氢给体数:
    4
  • 氢受体数:
    6

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
哺乳期使用概述:在哺乳期间短期或偶尔使用二氯醛苯那宗不太可能对哺乳的婴儿产生不利影响,特别是如果婴儿年龄超过2个月。由于活性代谢物三氯乙醇的半衰期较长,长期在哺乳期间重复使用可能会导致婴儿镇静,尤其是在哺乳新生儿或早产儿时。在组合偏头痛产品(例如,Midrin)中发现的低剂量二氯醛苯那宗不太可能导致婴儿嗜睡,除非每天多次重复剂量。二氯醛苯那宗中的安替比林成分被认为不太可能对婴儿造成伤害。监测婴儿是否有镇静、进食不良和体重增长不良的情况。 对哺乳婴儿的影响:一名5个月大的哺乳婴儿在其母亲每晚服用1.3克二氯醛苯那宗(相当于大约1克水合氯醛)加氯丙嗪100毫克每日3次的情况下,出现了轻微的早晨镇静。婴儿在3个月大时的整体发育被认为是正常的。 对泌乳和母乳的影响:截至修订日期,没有找到相关的已发布信息。
◉ Summary of Use during Lactation:Short-term or occasional use of dichloralphenazone during breastfeeding is unlikely to adversely affect the breastfed infant, especially if the infant is older than 2 months. Because the active metabolite, trichloroethanol, has a long half-life, long-term use of repeated doses during breastfeeding could result in infant sedation, especially while nursing a neonate or preterm infant. The low doses of dichloralphenazone found in combination migraine products (e.g., Midrin) are less likely to cause drowsiness in the infant unless doses are repeated several times daily. The antipyrine component of dichloralphenazone is considered unlikely to harm the infant. Monitor the infant for sedation, poor feeding and poor weight gain. ◉ Effects in Breastfed Infants:Minimal morning sedation occurred in a 5-month-old breastfed infant whose mother was taking 1.3 grams of dichloralphenazone (equivalent to about 1 gram of chloral hydrate) every evening plus chlorpromazine 100 mg 3 times daily. The infant's overall development was said to be normal at 3 months of age. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.
来源:Drugs and Lactation Database (LactMed)

SDS

SDS:dee72a435d064d85e99ec018076e093f
查看

文献信息

  • [EN] COMPOUNDS AND THEIR USE AS BACE INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE
    申请人:ASTRAZENECA AB
    公开号:WO2016055858A1
    公开(公告)日:2016-04-14
    The present application relates to compounds of formula (I), (la), or (lb) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
    本申请涉及式(I)、(Ia)或(Ib)的化合物及其药物组合物/制剂。本申请进一步涉及治疗或预防与Αβ相关的病理学,如唐氏综合症,β-淀粉样蛋白血管病,如但不限于脑淀粉样蛋白血管病或遗传性脑出血,与认知损害相关的疾病,如但不限于MCI(“轻度认知损害”),阿尔茨海默病,记忆丧失,与阿尔茨海默病相关的注意力缺陷症状,与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病,包括混合性血管性和退行性起源的痴呆,早老性痴呆,老年性痴呆和与帕金森病相关的痴呆的方法。
  • [EN] METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] MÉTHYLOXAZOLES ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
    申请人:MERCK SHARP & DOHME
    公开号:WO2016089721A1
    公开(公告)日:2016-06-09
    The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及甲基噁唑化合物,其为促进睡眠的受体拮抗剂。本发明还涉及所述化合物在潜在治疗或预防涉及促进睡眠的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及促进睡眠的疾病中的用途。
  • HETEROBICYCLIC COMPOUNDS
    申请人:Amgen Inc.
    公开号:US20130225552A1
    公开(公告)日:2013-08-29
    Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.
    Formula (I)的杂环化合物: 或其药用可接受的盐、互变异构体或立体异构体,如规范中所定义,并含有它们的组合物,以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法,如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
  • [EN] NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] COMPOSÉS DE NAPHTHALÈNE CARBOXAMIDE, MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1
    申请人:MERCK SHARP & DOHME
    公开号:WO2011149801A1
    公开(公告)日:2011-12-01
    The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    本发明涉及式(I)的萘甲酰胺化合物,它们是M1受体阳性变构调节剂,可用于治疗M1受体参与的疾病,如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物的药物组合物,以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
  • [EN] COMT INHIBITING METHODS AND COMPOSITIONS<br/>[FR] PROCÉDÉS D'INHIBITION DE LA COMT ET COMPOSITIONS ASSOCIÉES
    申请人:LIEBER INST FOR BRAIN DEV
    公开号:WO2016123576A1
    公开(公告)日:2016-08-04
    The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.
    这些发明包括一种抑制受试者中COMT酶的方法,以及式I的化合物或其药用可接受盐,这些化合物在治疗由COMT介导的各种疾病中有用,包括帕金森病和/或精神分裂症。
查看更多